Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C

被引:3
|
作者
Posada-Cespedes, Susana [1 ,2 ]
Van Zyl, Gert [3 ,4 ]
Montazeri, Hesam [5 ]
Kuipers, Jack [1 ,2 ]
Rhee, Soo-Yon [6 ]
Kouyos, Roger [7 ,8 ,9 ]
Guenthard, Huldrych F. [7 ,8 ,9 ]
Beerenwinkel, Niko [1 ,2 ]
机构
[1] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland
[2] SIB Swiss Inst Bioinformat, Basel, Switzerland
[3] Stellenbosch Univ, Fac Med & Hlth Sci, Div Med Virol, Cape Town, South Africa
[4] Natl Hlth Lab Serv, Cape Town, South Africa
[5] Univ Tehran, Inst Biochem & Biophys, Dept Bioinformat, Tehran, Iran
[6] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[7] Univ Hosp Zurich, Div Infect Dis, Zurich, Switzerland
[8] Univ Hosp Zurich, Hosp Epidemiol, Zurich, Switzerland
[9] Univ Zurich, Inst Med Virol, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
CANCER PROGRESSION MODELS; DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; EVOLUTIONARY PATHWAYS; PROTEASE; PATTERNS; DIVERSITY; EMERGENCE; SEQUENCES;
D O I
10.1371/journal.pcbi.1008363
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Author summary There is a disparity in the distribution of infections by HIV-1 subtype in the world. Subtype B is predominant in America, Australia and western and central Europe, and most therapeutic strategies are based on research and clinical studies on this subtype. However, non-B subtypes represent the majority of global HIV-1 infections; e.g., subtype C alone accounts for nearly half of all HIV-1 infections. We present a statistical framework enabling the comparison of patterns of accumulating mutations in different HIV-1 subtypes. Specifically, we compare the temporal ordering of lopinavir resistance mutations in HIV-1 subtypes B versus C. To this end, we combine the Hidden Conjunctive Bayesian Network (H-CBN) model with an approximate inference scheme enabling comparisons of larger networks. We show that the development of resistance to lopinavir differs significantly between subtypes B and C, such that findings based on subtype B sequences can not always be applied to sybtype C. The described methodology is suitable for comparing different subgroups in the context of other evolutionary processes. Although combination antiretroviral therapies seem to be effective at controlling HIV-1 infections regardless of the viral subtype, there is increasing evidence for subtype-specific drug resistance mutations. The order and rates at which resistance mutations accumulate in different subtypes also remain poorly understood. Most of this knowledge is derived from studies of subtype B genotypes, despite not being the most abundant subtype worldwide. Here, we present a methodology for the comparison of mutational networks in different HIV-1 subtypes, based on Hidden Conjunctive Bayesian Networks (H-CBN), a probabilistic model for inferring mutational networks from cross-sectional genotype data. We introduce a Monte Carlo sampling scheme for learning H-CBN models for a larger number of resistance mutations and develop a statistical test to assess differences in the inferred mutational networks between two groups. We apply this method to infer the temporal progression of mutations conferring resistance to the protease inhibitor lopinavir in a large cross-sectional cohort of HIV-1 subtype C genotypes from South Africa, as well as to a data set of subtype B genotypes obtained from the Stanford HIV Drug Resistance Database and the Swiss HIV Cohort Study. We find strong support for different initial mutational events in the protease, namely at residue 46 in subtype B and at residue 82 in subtype C. The inferred mutational networks for subtype B versus C are significantly different sharing only five constraints on the order of accumulating mutations with mutation at residue 54 as the parental event. The results also suggest that mutations can accumulate along various alternative paths within subtypes, as opposed to a unique total temporal ordering. Beyond HIV drug resistance, the statistical methodology is applicable more generally for the comparison of inferred mutational networks between any two groups.
引用
收藏
页数:25
相关论文
共 50 条
  • [41] Comparative biochemical analysis of wildtype and drug resistant HIV-1 integrase subtypes B and C
    Tamara Bar-Magen
    Richard D Sloan
    Emily I McDonough
    Verena Faltenbacher
    D Aaron Donahue
    Bjorn D Kuhl
    Hongtao Xu
    Mark A Wainberg
    Retrovirology, 6
  • [42] Primo and experienced HIV-1 drug resistance analysis connected with HIV-1 subtypes among HIV infected patients in Hungary
    Ujhelyi, E.
    Barbai, V. H.
    Szlavik, J.
    Banhegyi, D.
    Sarvari, C.
    JOURNAL OF CLINICAL VIROLOGY, 2009, 46 : S29 - S29
  • [43] HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen
    Lafeuillade, A
    Solas, C
    Chadapaud, S
    Hittinger, G
    Poggi, C
    Lacarelle, B
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (04) : 462 - 464
  • [44] Prevalence of HIV-1 Subtypes and Antiretroviral Drug Resistance Mutations in Nepal
    Bhusal, Nirajan
    Sutthent, Ruengpung
    Horthongkham, Navin
    Athipanyasilp, Niracha
    Kantakamalakul, Wannee
    CURRENT HIV RESEARCH, 2016, 14 (06) : 517 - 524
  • [45] A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C
    Boyer, Paul L.
    Rehm, Catherine A.
    Sneller, Michael C.
    Mican, JoAnn
    Caplan, Margaret R.
    Dewar, Robin
    Ferris, Andrea L.
    Clark, Patrick
    Johnson, Adam
    Maldarelli, Frank
    Hughes, Stephen H.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
  • [46] Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes
    Fofana, D. B.
    Charpentier, C.
    Maiga, A. I.
    Lambert-Niclot, S.
    Sayon, S.
    Simon, A.
    Katlama, C.
    Yazdanpanah, Y.
    Descamps, D.
    Calvez, V.
    Marcelin, A. G.
    Soulie, C.
    ANTIVIRAL THERAPY, 2014, 19 : A114 - A114
  • [47] Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes
    Charpentier, Charlotte
    Lambert-Niclot, Sidonie
    Alteri, Claudia
    Storto, Alexandre
    Flandre, Philippe
    Svicher, Valentina
    Perno, Federico
    Brun-Vezinet, Francoise
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Ceccherini-Silberstein, Francesca
    Descamps, Diane
    PLOS ONE, 2013, 8 (01):
  • [48] In vitro selection of novel etravirine-associated resistance mutations in B and non-B HIV-1 subtypes
    Asahchop, E. L.
    Tremblay, C. L.
    Brenner, B. G.
    Oliveira, M.
    Moisi, D.
    Toni, T.
    Spira, B.
    Wainberg, M. A.
    ANTIVIRAL THERAPY, 2010, 15 : A134 - A134
  • [49] Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes
    Fofana, Djeneba B.
    Charpentier, Charlotte
    Maiga, Almoustapha I.
    Lambert-Niclot, Sidonie
    Sayon, Sophie
    Desire, Nathalie
    Simon, Anne
    Yazdanpanah, Yazdan
    Katlama, Christine
    Descamps, Diane
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    Soulie, Cathia
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (01) : 130 - 135
  • [50] Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
    Barragan, Patricia
    Podzamczer, Daniel
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2363 - 2375